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Abstract
Introduction. The arteriovenous fistula (AVF) dysfunction is a common reason for vascular access problem in 
chronically hemodialyzed patients. It is caused by stenosis or occlusion located either in inflow artery, anastomosis 
or outflow vein. Revascularization of these pathologies can be achieved in surgical or endovascular (PTA) manner. 
The aim of this study was to evaluate both immediate and late endovascular treatment results of dysfunctional 
fistulas in chronically hemodialyzed patients.
Material and methods. We included in our observation 106 patients with end stage renal disease, who un-
derwent PTA within arteriovenous fistulas. We used conventional and unified techniques of endovascular therapy. 
Procedural results were evaluated after 1, 3, 6 and 12 months based on fistula sufficiency during hemodialysis.
Results. In 96 (90.6%) cases the initial result of PTA was good. We achieved improvement in blood flow 
through AVF and successful hemodialysis. In 10 cases (9.4%) results were not satisfactory. None of our patients 
developed neither worsening in the blood flow through AVF nor compromised blood circulation distally to AVF. 
No serious complications (MI, stroke, death) occurred during procedure or hospital stay. After 12 months, 
in 52 patients AVF were functioning properly. In 20 cases, because of fistula dysfunction, reintervention was 
necessary (primary patency 66%). Considering all patients, also these with successful reintervention, 69 AVF 
were functioning properly after 12 months (secondary patency 86%). 
Conclusions. To conclude, the immediate and long-term PTA outcomes of arteriovenous fistulas with currently 
available techniques and equipment are satisfying. PTA is a safe manner of prolonging patency rate of AVF in 
patients requiring permanent hemodialysis.
Key words: arteriovenous fistula, hemodialysis, percutaneous transluminal angioplasty, 
revascularization 
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Introduction
While the chronic kidney disease and end-stage 
renal disease (ESRD) population is continuously expand- 
ing [1, 2] functional vascular access ensures an adequate 
and effective dialysis in this group of patients. Native 
arteriovenous fistulae (AVF) are the best and most 
durable access for hemodialysis [3]. Catheters, on the 
contrary, have high rates of infection and thrombosis 
and should be used when fistulae and grafts cannot be 
fashioned [4]. 
The AVF dysfunction is a common cause for vascular 
access problem in chronically hemodialyzed patients. 
It is due to stenosis or occlusion located in the inflow 
artery, anastomosis or outflow vein.
Access dysfunction may be caused by stenotic le-
sion as a result of neointimal hyperplasia at the surgical 
anastomosis [5] and may lead to thrombosis [6] and 
subsequent access failure. Such complications occur 
frequently, increasing patient’s morbidity and creating 
additional costs for healthcare system.
Percutaneous transluminal angioplasty (PTA) is an 
accepted treatment for obstructive lesions. Although 
the rate of restenosis after endovascular intervention 
remains high [7], it appears to be the optimal treatment 
modality. Patency of a vessel after percutaneous angio-
plasty has been shown to be equivalent with surgical 
treatment though endovascular approach generates 
less complications [8, 9].
The purpose of our study was to determine the 
immediate and long-term clinical effects of PTA of 
dysfunctional native fistulae using currently available 
endovascular techniques.
Material and methods
A consecutive series of 106 ESRD patients treated 
with hemodialysis (HD) and requiring endovascular AVF 
repair were included in the study. They were referred 
to the Department of Angiology, Jagiellonian University 
Medical College, Krakow, Poland (JUMC) — tertiary, 
high volume interventional therapy center. Data were 
systematically collected, anonymized and analyzed inde-
pendently for treatment outcomes. Study was planned 
and executed according to ethical 5 standards of local 
Ethics Committee. As all the data were fully anonymized 
before analysis, no formal consents and approvals were 
necessary, except for the routine informed consent for 
imaging and PTA according to hospital procedures. 
Population
All patients were treated with maintenance HD 
3 times a week. Hemodialysis vintage ranged between 
8 and 81 months (mean 45.6 19.0 months). There were 
no cases of inadequate fistula maturation or concom-
itant central vein occlusion. In 69 referred patients 
AVF was a ‘primary’ access (first AVF, with no history 
of surgical reconstruction or previous endovascular 
procedures). Five patients experienced single surgical 
reconstruction before present referral, 23 — two 
reconstructions and in 10 patients 3 surgical recon-
structions were performed. No previous endovascular 
procedures were performed in any analyzed AVF. 
Demographic and clinical profiles of study subjects are 
shown in Table I.
All referrals for intervention were based on the 
standard Kidney Disease Outcomes Quality Initiative 
(KDOQI) and the ‘Fistula First’ approach [10–12] as 
well as local standards at referring HD centers, which 
suggest intervention if one or more of the following oc-
cur: abnormalities on physical examination, poor dialyzer 
blood flow (< 200 mL/min), elevated venous/arterial 
pressure detected on HD monitor, increased bleeding, 
inability to cannulate, or decrease in dialysis adequacy 
measured by dialysis index Kt/V < 1.2 [13] or URR 
< 65% [14]. Referral details are summarized in Table 2. 
Functional Doppler ultrasound of AVF were per-
formed in all patients before procedure in order 
to locate the stenotic segment (later confirmed in 
angiography) and to assess AVF anatomy for further, 
post-procedural monitoring. Significant stenosis was 
defined as a reduction in luminal diameter of more than 
50% on access angiogram. 
Table 1. Demographic and clinical profiles of studied subjects 
n (%)
Age (years) 62.2
Males 59 (55.1)
Coronary artery disease, including: 47 (43.9)
Myocardial infarction 20 (18.7)
History of coronary artery  
angioplasty 
16 (14.9)
History of CABG 7 (6.5)
Atrial fibrillation 4 (3.7)
Congestive heart failure 19 (17.8)
History of stroke/TIA 6 (5.6)
Hypertension 79 (73.8)
Hemodialysis 107 (100)
Diabetes 40 (37.4)
On insulin 34 (31.8)
On oral medication 2 (1.9)
COPD 9 (8.4)
Asthma 2 (1.9)
Cigarette smoking 10 (9.3)
History of cigarette smoking 14 (13.0)
Data are presented as numbers (and percentages). CABG — coronary artery 
bypass grafting; COPD — chronic obstructive pulmonary disease; TIA — tran-
sient ischemic attack
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AVF characteristics and technical procedure 
description
All arteriovenous fistulae were native forearm or 
arm fistulae created as anastomoses between the side 
or end segments of radial or brachial artery with the 
adequate segments of cephalic or basilic vein. They 
were stenosed in 72 (67.3%) patients and occluded/ 
/thrombosed in 35 (32.7%) patients. Stenosis within 
the inflow artery was found in 24 (22.4%) cases, within 
anastomosis in 52 (48.6%) and in outflow vein in 101 
cases (94.4%) respectively. 
In the group of patients with occluded fistulae, 
concomitant occlusion of inflow artery, anastomosis 
and outflow vein was observed in 15 cases, whereas 
occlusion of anastomosis and outflow vein in seven cases 
and outflow vein only — in thirteen.
Vascular access for procedure was established by 
cannulation of common femoral artery (90 patients — 
85%), brachial artery (7 patients — 6.6%) or distal 
portion of fistula’s outflow vein (9 patients — 8.4%). 
Doppler ultrasound was done before all attempts to 
puncture femoral artery. In case of occlusion or sig-
nificant stenosis of femoral, iliac arteries or in cases 
of chronic total occlusion of subclavian artery, which 
proved to be impossible to treat due to technical rea-
sons, brachial artery or fistula was punctured. Classic 
Seldinger method was used. In cases of femoral access 
a 90 cm long 6Fr sheath (Brite Tip, Cordis, Miami 
Lakes, USA) was placed in proximal brachial or axillar 
artery. In the remaining patients, a standard 5 Fr 11 cm 
long sheath was used. Once the vascular access was 
established, the AV fistula was cannulated in a standard 
fashion, using 0.035” (Radifocus guide wire M, Terumo, 
Leuven, Belgium) or 0,018” (V-18 Control Wire, Bos-
ton Scientific, Galway, Ireland) hydrophilic wires and 
standard angiographic catheters.
All patients underwent prolonged POBA angioplasty 
(Plain Old Balloon Angioplasty) (3 minutes [IQR 1.8– 
–3.5 min]) of stenosed or thrombosed vessels. Standard 
balloon catheters with dimensions ranging from 3 mm 
to 6 mm (depending on respective vessel diameter) 
were used (Passeo, Biotronik, Bullach, Switzerland; 
Powerflex Pro, Cordis, Miami Lakes, USA; Armada, 
Abbott Vascular, Santa Clara, USA) (Fig. 1). In 12 pa-
tients (11.2%) isolated angioplasty was not satisfactory. 
In these few cases angioplasty with scoring balloon 
(AngioScore, Biotronik, Bulach, Switzerland) was per-
formed with good angiographic result. 
Thrombosed fistulae were treated using the same 
technique with hydrophilic guidewires and balloon 
catheters. Due to inadequate reimbursement in the 
Polish Health System, drug-eluting balloon angioplasty 
was not used. Stents or declotting devices have never 
been necessary in our experience to improve the final 
result. Moreover, due to the location of treated vessels 
and need for repetitive vessel punctures during hemo-
dialises, the use of stents is controversial. For these 
reasons they were not utilized.
Procedural success was defined as an achievement of 
a satisfactory final residual diameter stenosis (< 30%) by 
Figure 1. Prolonged Plain Old Balloon Angioplasty of arteriovenous fistula. A. Pre PTA; B. PTA; C. Post PTA; 1 — inflow artery; 
2 — anastomosis; 3 — outflow vein; 4 — stenosis; 5 — balloon catheter
Table 2. Referral details 
n (%)
Poor dialyzer blood flow (< 200 mL/min) 98 (91.6)
Elevated venous/arterial line pressure on 
HD monitor
87 (81.3)
Increased bleeding and/or inability  
to cannulate
19 (17.7)
Kt/V < 1.2 91 (85.0)
URR < 65% 85 (79.4)
Kt/V — dialyzer clearance of urea multiplied by dialysis time and divided by 
volume distribution of urea; URR — urea reduction ratio
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quantitative angiography at the end of the procedure 
(without flow-limiting dissection or hemodynamically 
significant gradient). Periprocedural treatment and 
monitoring were standardized. Site closure devices 
were used sporadically (AngioSeal, St. Jude Medical, 
Zaventem, Belgium). Puncture site was examined on 
the first day after procedure by Doppler ultrasound for 
any puncture site complications (arterio-venous fistula, 
pseudoaneurysm, dissection). Hemodialysis was per-
formed on the day before and after the procedure in all 
patients. Limited evidence exists on the periprocedural 
administration of heparin and antiplatelet drugs. Based 
on available reports and center experience patients 
received 75 mg/day of aspirin daily; in addition they 
received 40 mg/day of enoxaparine for the first month 
after the procedure (HD — free days). 
Fistula efficiency during HD was repeatedly verified 
the day after procedure and then on months 1, 3, 6 
and 12 post-procedure. Well-functioning AVF has been 
defined by means of quantitative parameters of dialysis 
adequacy, i.e.: 
 — Kt/V > 1.2–1.4, 
 — URR < 68–70% and 
 — dialyzer blood flow ranging between 250 and 400 mL/ 
/min. 
All criteria had to be met to confirm AVF function. 
Dysfunction of AVF without possibility for future suc-
cessful revascularization or patient death were defined 
as treatment failure.
Statistical analysis
Statistical analysis was performed using SPSS pack-
age (SPSS Inc. Released 2009. PASW Statistics for Win-
dows, Version 18.0. Chicago: SPSS Inc.). Variables were 
evaluated in descriptive statistics. Data were analyzed 
in respective contingency tables. Mann-Whitney-U test 
and chi-squared test (with Yates correction if applicable) 
were used to assess differences. P-values less than 0.05 
were considered as statistically significant. Kaplan-Meier 
estimator curve was generated using R survival package 
(Therneau T [2014] A Package for Survival Analysis in 
S. R package version 2.37–7).
Results
As the monitoring pattern of dialysis parameters 
in referring centers was highly inconsistent, it was not 
possible to retrieve specific numerical data on Kt/V, 
URR, and dialyzer flow changes in many cases. Thus 
we decided to approach post procedural follow-up 
in a simplified way (see methods section). Meeting all 
3 criteria combined with procedural success was con-
sidered a treatment success; it was achieved in 96 cases 
(90.6%). In 4 patients (3.7%) we were not able to pass 
through the occluded vein and in 6 (5.6%) cases there 
was little or no improvement in blood flow through 
AVF despite of apparently successful PTA. None of our 
patients developed neither worsening in the blood flow 
through AVF nor compromised blood circulation distally 
to AVF. We did not observe any serious complications 
(including myocardial infarction, stroke, or death) dur-
ing the procedure or hospital stay. 
Post-procedural course was uneventful except for 
single case of 17 mm diameter pseudoaneurysm. It was 
successfully treated by local thrombin injection. However, 
up to 30 days post procedure, there were 3 deaths which 
— according to the opinion of physicians in charge of the 
patients — were not attributed to the index procedure. 
Seventeen deaths were noted within the whole observa-
tional period, but these events could not be meaningfully 
related to endovascular procedure (Tab. 3). 
Final analysis (12 months following the procedure) 
included 79 patients who remained alive. 
Fifty two AVF were functioning properly after 12 
months. The probability of the intervention-free surviv-
al is shown in Kaplan-Meier estimator curve (Fig. 2). In 
20 cases reintervention was performed while 7 others 
with recurrence of fistula dysfunction did not agree for 
reintervention (66% of proper fistula function without 
reintervention at 1 year). Time distribution of reinter-
vention in the follow-up period is shown in Figure 3. 
Out of all 20 AVF that were subjects of reinter-
ventions, in 4 of them the result of the initial PTA was 
already not satisfactory. Considering all patients (includ-
ing those with successful reintervention), 69 AVF were 
functioning properly at 12 month (87%). 
There was no correlation between the location of 
lesion (inflow artery, anastomosis, outflow vein) and 
initial or long-term PTA results. Similarly, the type of 
balloon catheter were not related to PTA outcome. 
Transfemoral approach allowed full rheological im-
aging of entire vasculature of limb with AVF and direct 
visualization of arterial part of AVF. There were no 
differences in procedural outcomes and patient’s safety 
measures dependent on access site. No puncture site re-
lated complications were observed in 1 year follow-up. 
AVF thrombosis was associated with significantly higher 
PTA failure rate as compared to stenosis (2.6% vs. 
13.1%; p = 0.003).
Other clinical and demographic factors did not 
influence PTA results. 
Discussion
The dysfunctions of arteriovenous fistulae in our 
patients were predominantly caused by stenosis, much 
less frequently by occlusions. Similar observation was 
made by other authors [15–17]. 
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Pathologies within arteriovenous fistulae were 
mainly located in the outflow vessels. The inflow artery 
was the least frequent location, which also correlates 
with observation from other studies [2, 15, 16]. Ob-
structive lesions of AVF require either endovascular or 
surgical revascularization. Percutaneous angioplasty of 
dysfunctional fistulae is a safe treatment modality. In 
our study, similar to that of other authors [15, 17, 18], 
periprocedural SAE (serious adverse events) included 
a single case of iatrogenic pseudoaneurysm effectively 
treated by thrombin injection. We did not encounter 
any deterioration of blood flow within the treated arm. 
The 3 deaths, which occurred up to 30 days after the 
procedure, were not related to endovascular treatment.
From our observation, technical success of the 
procedure was achieved in 90.6% of patients. The 
observed 66% of sufficient clinical effects without 
clinically driven reintervention and 87% with reinter-
vention in our patients are noteworthy. It is important 
to emphasize that the majority of studies available in 
literature that present results of endovascular treat-
ment of dysfunctional AVF do not rely on single end-
ovascular technique. Frequently, PTA is combined 
with thrombolysis, thromboaspiration or mechanical 
thromboaspiration. Natário et al. supplemented PTA with 
thromboaspiration technique reaching primary patency 
(PP) of 51% and secondary patency (SP) of 96% [19]. 
In other studies, urokinase or r-tPA (recombinant tis-
sue plasminogen activator) were used in combination 
with PTA. The treatment results were similar to those 
presented in the studies where only PTA was used: PP 
18–70%, SP — 63–81% [20–23].
Table 3. Serious adverse events 
Serious adverse events
30 days 1–12 months
Death 3 14
Myocardial infarction 0 5
TIA/stroke 1 0
Congestive heart failure 2 2
Urgent surgical intervention 0 0
Urgent endovascular intervention 0 0
Pseudoaneurysm 1 0
Causes of death 0–12 months (n = 17)
Myocardial infartion 4
Stroke 1
Congestive heart failure 3
Respiratory failure 1
Cardiac arrest 1
Sepsis 1
Unknown 6
Figure 2. The probability of intervention-free survival 
(Kaplan-Meier estimator curve)
Figure 3. Periodic and cumulative re-intervention rate during 
1 year follow-up
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Vascular access through femoral artery and the 
use of long sheaths to manage AVF may not be widely 
utilized, but has clear advantages. It enables easy visu-
alization of all the inflow and outflow vessels, including 
the subclavian and axillary arteries and safe cannulation 
of radial artery even in the cases of its atypical (high) 
origin. What is needed, though, are long shaft catheters 
and wires. The brachial artery is quite mobile and may 
prove to be difficult to cannulate. Moreover, pressure 
that has to be applied on brachial artery in order to 
obtain hemostasis may jeopardize the function of the 
fistula itself. The radial artery may originate from proxi-
mal brachial or even axillary arteries, so typical brachial 
puncture may not provide an access to the fistula. On 
the other hand, retrograde cannulation of the AVF, using 
an outflow vein as access, may be quite cumbersome 
as the fistula usually cannot be sufficiently visualized by 
injecting the dye into the outflow vein. It seems quite 
advisable to be skillful in gaining access through each of 
the sites and choose them according to the needs, for 
example, cannulate the fistula in a retrograde manner 
when an attempt at antegrade cannulation fails. In such 
a case, one may benefit from good visualization of the 
vessels provided by dye injection into arterial sheath 
when cannulating the fistula from the venous side.
PTA of main outflow vein was supplemented in 
some studies by coiling of its branches. Hence, the 
blood flow could be directed from fistula to the main 
outflow vessel, thus increasing the flow through AVF 
[14, 18]. However, the results of PP (59–60%) and 
SP (90%) are comparable to those from other studies 
where only PTA was used.
In our study, the location of fistula’s pathology had 
no significant impact neither on immediate nor long- 
-term results of endovascular treatment. We observed 
significantly worse results of endovascular treatment of 
occluded fistulas compared to those with stenosis. Similar 
to our conclusion, Manninen et al. noticed no correlation 
between the location of lesions patency of fistulas. In con-
trast, they did not confirm any correlation between the 
type of pathology (stenosis vs occlusion) and PP rates [15]. 
Raynaud et al. observed significantly higher number of 
restenosis within the venous part of fistulas [24].
It has been shown that the long-term clinical effects 
after endovascular treatment of obstructive AVF lesions 
have improved over the past years, and are parallel with 
our own observations [17, 19, 25–28]. It may be related 
to the availability of low profile, high pressure balloons 
and growing experience of interventional teams.
The outcomes of surgical and endovascular treat-
ment are corresponding to each other [29]. Due to 
the reasons that there is only a small number of trials 
comparing these two methods [29] and no available 
guidelines, it is not possible to make an evidence-based 
decision regarding the choice of treatment. Frequent-
ly, the choice of particular technique is limited to the 
practiced method in the specific centre. 
Endovascular techniques are less invasive than 
surgery. Moreover, after percutaneous angioplasty, 
treated fistula can be catheterized sooner and used 
as an effective hemodialysis access (usually after two 
weeks). In the case of surgical procedure, this period 
is significantly longer [30].
There is little evidence to support the mentioned 
course of pharmacological treatment and it is incon-
clusive if antiplatelet or anticoagulant therapy should 
be used in patients after AVF repair. Since appropriate 
pharmacological therapy can influence immediate and 
long-term treatment results of AVF dysfunction, this 
subject should be addressed in further studies.
Conclusions
The immediate and long-term outcomes of percuta-
neous transluminal angioplasty of arteriovenous fistulas 
with currently available techniques and equipment are 
satisfying. 
Percutaneous angioplasty is a safe manner of pro-
longing patency rate of arteriovenous fistulas in patients 
requiring permanent hemodialysis.
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